Skip to main content
| News

Vaximm is using AI to develop cancer vaccines

12.11.2019

Basel-based biotech company Vaximm has agreed a collaboration with IT company NEC. Vaximm wants to develop personalized cancer vaccines using NEC’s artificial intelligence (AI)-based prediction system.

Vaccine (Img: PhotoLizM/Pixabay)

According to a press release by Vaximm, Vaximm and NEC have agreed to cooperate on a non-exclusive basis. As part of the collaboration, NEC will make an equity investment in Vaximm. In addition, the Tokyo-based IT company will provide funding for a Phase I clinical trial for personalized neoantigen cancer vaccines.

The two partners want to develop the vaccines through the agreed collaboration. Vaximm will provide its experience in developing oral T-cell immunotherapies for patients, while NEC has developed a neoantigen prediction system based on state-of-the-art artificial intelligence (AI) technology, which is to be utilized in the development of cancer vaccines. Vaximm will manage the clinical trial scheduled for the coming year. NEC has secured the development and commercialization rights to the program worldwide, except for China and other Asian territories, which also apply to Japan.

Heinz Lubenau, PhD, Chief Operating Officer and Co-Founder of Vaximm, said: “NEC’s novel AI technology will enable not only the identification but also the prioritization of neoantigens from each patient. Once the list of neoantigens is available, we will be able to apply our technology to quickly produce a personalized vaccine. “

Vaximm is headquartered in the Technology Park, Basel. The location will be pleased to hear another success story from one of its companies based there. This means an extension of the cooperation between NBE Therapeutics and the Czech biotech company Sotio. NBE Therapeutics specializes in developing antibody drug conjugate products for cancer treatment. The two companies want to work together to develop next-generation antibody drug conjugates. Sotio has now exercised the option for developing a second drug candidate. NBE Therapeutics will also be able to use its in-house platform for this, while Sotio has the corresponding commercial rights. The exercise of the option by Sotio will give NBE the right to receive certain payments.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Space Pharmaceuticals establishes presence in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Space Pharmaceuticals establishes presence in Basel

Space Pharmaceuticals AG is strengthening the life sciences cluster in the Basel Area. At its research lab, the cheminformatics company...

Read More
NextImmune to benefit from Venture Kick financing
Basel Area Business & Innovation, Innovation, Life Sciences / biotech

NextImmune to benefit from Venture Kick financing

The startup accelerator Venture Kick is supporting NextImmune with financing in the amount of 150,000 Swiss francs. The spin-off from...

Read More
OECD impressed by the canton of Jura’s innovation system
Basel Area Business & Innovation, Innovation, Medtech, Switzerland Innovation Park

OECD impressed by the canton of Jura’s innovation system

The OECD has examined the innovation systems in place in rural areas of its member states, including the canton of...

Read More
ti&m opens branch in Basel
Basel Area Business & Innovation, ICT, Innovation, Invest

ti&m opens branch in Basel

ti&m now has an office in Basel. With this action, the company specializing in digitization, security and innovation projects is...

Read More
What can artificial intelligence do for health?
Basel Area Business & Innovation, Digital Health, Innovation, Life Sciences / biotech, Medtech

What can artificial intelligence do for health?

Algorithms help diagnose and treat diseases, discover new drugs and personalize prevention. Thus, the potential of artificial intelligence has been...

Read More
Economic promotion agency creates 55 new jobs in Jura
Basel Area Business & Innovation, Innovation, Invest, Switzerland Innovation Park

Economic promotion agency creates 55 new jobs in Jura

The economic promotion agency of the canton of Jura supported a total of 26 companies in founding, establishing a presence...

Read More
Investors top up capital of BioVersys
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Investors top up capital of BioVersys

BioVersys has raised 24.2 million Swiss francs in a series C funding round. The Basel-based pharmaceutical company plans to use...

Read More
Swiss made software label awarded to 1000th company
Basel Area Business & Innovation, ICT, Innovation

Swiss made software label awarded to 1000th company

Swiss made software GmbH has now awarded its seal of quality to its 1,000th member firm. The “swiss made software”...

Read More
EvokAI to acquire Advancience
Basel Area Business & Innovation, Digital Health, Innovation, Invest, Medtech

EvokAI to acquire Advancience

EvokAI Creative Labs Inc. has agreed a deal to acquire Advancience. The diagnosis profiles enhanced by Artificial Intelligence (AI) developed...

Read More
BeiGene opens European headquarters in Basel
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

BeiGene opens European headquarters in Basel

BeiGene has opened its new European headquarters in Basel. The global biotech specializing in innovative cancer treatments intends to build...

Read More
1 2 3 34

Do you have a question? We'd like to hear from you.